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ABSTRACT 
Hypertension is the one of leading causes of the disease burden worldwide. 
Hypertension affects approximately 37-55% population of the developed 
countries and the genetic susceptibility to it could be an outcome of the inherited 
differences in the capacity of sodium retention.CYP3A5 enzyme has been 
implicated in the regulation of blood pressure (BP) and thus, may serve as a 
potential risk factor for the development of hypertension. Carriers of the 
CYP3A5*1 allele had high, whereas homozygous carriers of the CYP3A5*3 
allele exhibit low CYP3A5 expression in the kidney where it represents the 
major isoform of the CYP3A family. The aim of the present hospital based case 
control study was to investigate the association of the CYP3A5*1 rs776746 
(6986  𝐴 → 𝐺 ) allele with BP in hypertension cases and healthy controls in a 
sample of Kashmiri population. The study included 150 hypertension patients 
(78 males and 72 females; age (mean ± S.D) 60.55 ± 11.19 years) and 
normotensive controls (79males and 71 females; age (mean ± S.D) 60.11±9.92 
years). The distribution of CYP3A5 genotype in hypertension cases and controls 
was assessed by PCR-RFLP method. Logistic regression was used to assess the 
relationship between CYP3A5 genotype and the risk of essential hypertension. 
Although CYP3A5*1 genotype was higher in cases (10%) than in controls 
(3.66%), however, it did not reach a statistically significance because of 
CYP3A5*3, which may have protective role against essential hypertension, as, 
was found to be statistically significant (OD=2.91, 95% CI: 1.43-9.94; P value= 
0.002). It was found that CYP3A5*1 carriers showed decrease in systolic blood 
pressure (SBP ) by 6.02 mmHg and an increase in diastolic blood pressure 
(DBP) by 2.50 mmHg, but, the results were not statistically significant. So, there 
is no association of CYP3A5*1 with the risk of essential hypertension. 
Keywords: CYP3A5, SBP, DBP, gene polymorphism  
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Chapter – 1 
Introduction 
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ssential Hypertension is a common vascular disease caused by a 
combination of genetic and environmental factors. It leads to heart and 
blood vessel damage resulting in hardening of the arteries, heart 
failure, stroke, kidneys, eyes, and brain damage. Hypertension affects around 
one billion people worldwide, adding to the workload of the heart and arteries 
(Wolf et al., 2003). Current statistics reveal that deaths due to ischemic heart 
disease and stroke are expected to rise to 10 million and 8 million respectively 
per year, in 2030 (World Health Statistics, 2007). Fifty percent of all Americans 
over the age of 60 are hypertensive. High blood pressure is directly responsible 
for the deaths of more than 35,000 Americans each year and is a contributing 
factor in the deaths of over 180,000 more. People with high blood pressure are 
seven times more likely to have a stroke and three times more likely to have a 
heart attack than those with normal blood pressure. In Kashmir, no scientific 
data is available but there are estimated 30% of hypertensive patients in 
Kashmir based on the medical registry of Sheri- Kashmir medical institute of 
medical sciences (SKIMS) and their number is increasing per year (Shahid et 
al., 2010). Essential hypertension is a common disorder. The term "common" 
has two implications: one that the disease is prevalent; and, second, that it is 
widespread. Such a frequency and distribution of characteristics could arise if 
the susceptibility alleles for hypertension were prevalent in the founding 
population of contemporary human beings and became distributed with humans 
globally. This common disease-common variant concept suggests that the 
genetic heterogeneity underlying hypertension susceptibility could be relatively 
small. Therefore, it makes sense that variation in genes related to hypertension 
should be studied. This becomes more important when there is little information 
about genetic variation and diversity in Kashmiri population available. In recent 
years the research is directed towards analysis of the disease on genetic level 
E 
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and explanation of the genetic basis of this disorder. Development of powerful 
and sensitive molecular genetic techniques has resulted in widespread 
endeavours to dissect the genetic factors and their molecular defects accounting 
for hypertension in various populations. Several non genetic factors may also 
substantially modify the relationships between genetic factors and blood 
pressure. Among these factors are age and dietary salt intake. Renal function, 
which is a crucial aspect of the regulation of blood pressure, decreases with age. 
It has been postulated that primary essential hypertension originates from an 
inherited inability of the kidney to excrete a sodium load in a sodium-rich 
environment. Monogenic forms of hypertension, although rare, are all 
associated with alterations in renal tubular sodium and water handling. 
Moreover, most genes identified as determinants of chronic blood pressure 
control in animal models are involved in the regulation of renal sodium 
reabsorption. Today, the state of the art approach towards the diagnosis of 
essential hypertension involves analysis of the genetic basis for the disorder. 
Single nucleotide polymorphism of hypertension related genes could help in 
developing sensitive assay for early diagnosis of susceptibility to hypertension. 
This will in turn, help patients to change eating habits and lifestyle accordingly 
to delay the onset of disease. Information about single nucleotide polymorphism 
may lead to more efficient drug design and even gene therapy. This study has 
been designed keeping in view the same benefits and is likely to be prerequisite 
to several other similar studies in genetic  diseases. So far genetic analysis of 
patients having essential hypertension, has been carried out in Kashmiri 
population on very limited scale. Any drug designing or development of 
diagnostic markers based upon genetic data has to be validated in our local 
population as it represents and closed homogeneous population not mixing with 
other ethnic groups for centuries. The objectives set in this study were to 
analyze loci thought to be linked with essential hypertension. 
Association of certain alleles with a disease phenotype can provide three 
pronged information. 1) Allele may itself be a causative factor, 2) Allele may be 
in linkage disequilibrium with causative locus nearby, 3) The association may be 
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due to chance, artefact or selection bias. Association studies require that controls 
selected are true controls (Agarwal et al., 2005). Development of extensive 
collections of single nucleotide polymorphisms (SNPs) raises the possibility that 
these SNPs could be used as markers in genome-wide association mapping 
studies to identify hypertension susceptibility loci (Kato, 2002). In this 
approach, large number of markers are typed in cases and controls with the 
expectation that markers interrogating SNPs that are involved in inheritance of 
disease susceptibility will emerge through their association with this trait in the 
affected population. It also allows the possibility that non random association of 
alleles (linkage disequilibrium, LD) can be used to reduce the number of SNP 
markers required to identify disease susceptibility alleles because a single 
marker can act as a surrogate for variation flanking it. The influence of a number 
of important factors in the detect ability of hypertension susceptibility alleles by 
SNP mapping approaches is not yet fully defined. These factors include the 
locus and allelic diversity of hypertension, the weaker relationship (compared 
with Mendelian traits) between genotype and phenotype, the accuracy of 
genotyping techniques, the extensive role of non genetic factors, the extent and 
heterogeneous nature of LD across the genome (Doris, 2002).  
Cytochrome P450 proteins are expressed in an organ-specific manner, with 
CYP3A5 predominantly expressed in the kidney (Haehner et al., 1996). As a 
glucocorticoid 6β-hydroxylase, the CYP3A5 enzyme converts cortisol or 
corticosterone to 6β-corticosterone, which may lead to increased sodium and 
water retention (Watlington et al., 1992; Ghosh et al., 1995). The CYP3A5 
gene has a common polymorphism (6986A→ G, rs776746) in the intron third. 
The G allele generates an aberrant RNA splicing site and results in a premature 
stop codon, which causes truncation of the CYP3A5 protein (Kuehl et al., 2001; 
Neville et al., 2012). In genetic epidemiology studies, CYP3A5*1 refers to the A 
allele (functional allele) and CYP3A5*3 refers to the G allele (nonfunctional 
allele). Recently, several studies have suggested a possible relationship between 
CYP3A5 gene polymorphisms and essential hypertension. 
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Hypertension continues to be a major cause of mortality in populations of the 
world and for which there is no known cause. However, till date, no study has 
been carried out to evaluate role of these polymorphism in relation to prevalence 
of essential hypertension in Kashmiri population. The aim of study is to 
investigate whether an association exists between selected polymorphism in 
CYP3A5 and essential hypertension. The significance of the proposed studies 
lies in their potential to legitimize or disproves a causative role for CYP3A 
activity in vertebrate renal physiology and to unmask possible molecular 
mechanisms underlying their effects. 
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2.1. Hypertension 
Hypertension or high blood pressure is not a disease but a symptom. It is hidden 
foe of humanity since a majority of the victims are asymptomatic. General 
hypertension can be defined as blood pressure levels above normal. It can be also 
defined as excessive tension or pressure that, if left untreated, will lead to 
increased morbidity or mortality in a particular susceptible group of patients at 
higher risk. Blood pressure is the force of blood pushing against the walls of 
arteries as it flows through them. Hypertension is one of the leading causes of 
disease burden worldwide. Hypertension affects approximately 37-55% of the 
adult population in Europe (Wolf et al., 2003). Hypertension prevalence is even 
higher in Africa, Asia and is a major cardiovascular risk factor for stroke, 
coronary artery disease, heart failure and end-stage renal disease, and it also 
increases cause of mortality (Lower et al., 1998). Currently, less than one third of 
hypertensive’s are treated and controlled (using the 140/90 mmHg threshold) 
(Wolf et al., 2003). The prevalence of hypertension in India varies from as much 
as 30% to as much as 61% (Gupta, 2011). The scenario of Kashmir is not 
different from the reported literature from different parts of India based on the 
medical registry of Sheri Kashmir medical institute of medical sciences (SKIMs), 
hypertension in Kashmir is found in almost 30% of population (Shahid et al.,  
2010).  The prevalence of hypertension is increasing in adolescents and children 
in some, but not all, countries which may lead to early development of adverse 
cardiovascular outcomes. These observations illustrate the high burden of 
hypertension in the general population across all age groups. There are two types 
of hypertension, essential or primary hypertension, and secondary hypertension. 
Although various lifestyle and dietary factors are associated with hypertension, 
specific biological determinants of primary or essential hypertension (as opposed 
to secondary forms of hypertension), which represents 95% of the hypertensive 
population, are still poorly understood. 
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 Blood pressure reading of 110/60 mmHg to 140/80 mmHg or below is 
considered to be within the normal range (Chobanian et al., 2003). These 
readings are for the normal person if some sort of preconditions exits for 
example older age, diabetes, or kidney failure, then even reading of 140/80 
mmHg is to be treated as hypertensive. Table 1 describes the different stages of 
Blood pressure as recommended by “Seventh Report of the Joint National 
Committee on Prevention, Detection, Evaluation, and Treatment of High Blood 
Pressure” (Chobanian et al., 2003). The first number (110 mmHg) is the 
systolic pressure, which measures the blood pressure in the arteries when the 
heart is contracting and pumping blood. The second number (60 mmHg) is the 
diastolic pressure, which measures the blood pressure in the arteries when the 
heart is at rest. Blood pressure sustained at over 140/90 mmHg is diagnosed as 
hypertension (Kumar et al., 1997). 
Magnitude of the arterial blood pressure is dependent upon cardiac output and 
total peripheral resistance. Cardiac output depends upon blood volume, which is 
greatly regulated by sodium homeostasis. 
Table 1. Different classes of blood pressure 
Category Systolic blood pressure 
(mm Hg) 
Diastolic blood 
pressure (mm Hg) 
Normal blood pressure  Below 120 Below 80 
Pre hypertensive  120-139 80-89 
Stage 1 hypertension  140-159 90-99 
Stage 2 hypertension  160 or higher 100 or higher 
Courtesy: (Chobanian et al., 2003). 
Total peripheral resistance is predominantly determined by lumen size of the 
arterioles. Lumen size is determined by thickness of the arteriolar wall and effect 
of hormones, which either constrict or dilate the vessels. 
Several factors influence blood pressure. The nervous system helps maintain 
blood pressure by adjusting the size of the blood vessels by use of constrictors 
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(α- adrenergic) and dilators (β-adrenergic), and by influencing the heart pumping 
action (Kumar et al., 1997). Kidneys assist in regulating blood pressure by 
adjusting mechanisms (for example, Renin- angiotensin system) that change 
blood volume (Rapp et al., 1990). Blood volume is maintained by sodium, 
mineralocorticoids, and atriopeptin and several vasoconstrictors for example 
angiotensin II, catecholamines, thromboxane, leukotrienes, and vasodilators (for 
example prostaglandins, kinins, nitric oxide-endothelium derived relaxing 
factors), regulate the peripheral resistance (Kumar et al., 1997). 
2.2. Risk Factors of Essential hypertension  
Based on cause of hypertension we classify hypertension into two types, 
essential or primary hypertension, and secondary hypertension. Ninety percent 
of all cases of hypertension fall into category of essential hypertension (Mathew 
and Sigmund, 2006).It is defined as high blood pressure with no apparent cause. 
However, there are so many factors associated with the development of essential 
hypertension including; 
Genetics – Chances of developing this disorder are high if it is in family 
(Hottenga et al., 2005; Mein et al., 2004) 
Race – for example, African Americans are more likely to develop hypertension 
as compared to Caucasians (Stewart et al., 2006). 
Gender and age - Males between 35-50, and females past menopause are at 
greater risk for developing for hypertension (Oparil, 2006). 
Diet – High salt or fat in the diet has been linked to the onset of hypertension 
(Svetkey et al., 1996). 
Weight - obesity (Stamler et al., 1976) (being more than 25% over ideal 
weight) is linked to the development of hypertension. 
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Lifestyle - smoking (Wilson et al., 1997) and alcohol consumption (Kannel et 
al., 1980) can increase blood pressure; also, sedentary lifestyle (Miall and 
Oldham, 1958) can increase hypertension. 
Psychosocial and environmental influence also play important role in inset of 
hypertension (Tomson and Lip, 2005). Actual outcome and intensity of 
hypertension is based upon collateral effort of some of these or even all of these 
factors (Dominiczak, 1999). 
Secondary hypertension is defined as high blood pressure caused by a pre-
existing physical condition such as renal, endocrine, cardiovascular, and 
neurological conditions. Most of the secondary hypertension is due to defect in 
single gene therefore; these are also called monogenic or Mendelian forms of 
hypertension. 
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Fig.1 Multiple interactions between genetic and environmental factors leading to 
hypertension (Maolian et al., 2006). 
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2.3. Cytochrome P450 Taxonomy 
The Cytochrome P450 (CYP) enzyme superfamily is an exceedingly diverse 
group with members found among organisms in every taxonomic kingdom 
(Nelson, 1999). The CYP are hemoproteins that have absorption maxima near 
450 nm. CYP enzymes catalyze the oxidations and reductions of a wide array of 
substrates. CYPs are divided into roughly 237 numbered families on the basis of 
sequence homology: 19 family members share greater than 40% sequence 
similarity and subfamily members are more than 55% similar (Nelson et al., 
1996). Sixteen CYP families are found among mammals (Nelson, 1998). In 
addition to their handling of endogenous molecules, members of the first three 
families are also known to metabolize exogenous, or xenobiotic, compounds 
including therapeutic drugs (Williams et al., 2004). CYP1-3 proteins constitute 
the phase I drug metabolizing enzymes, which catalyze the fictionalization of 
their substrates via reactions (e.g., hydroxylation and demethylation) that 
increase aqueous solubility or introduce attachment sites for bulkier moieties to 
be added by phase II enzymes.CYP proteins are expressed in the liver and 
throughout the gastrointestinal tract, where the bulk of first-pass drug 
metabolism occurs (Chhabra, 1979). The generally non-CYP phase II enzymes 
including glutathione S-transferase, sulfotransferases, and N-acetyl transferase 
conjugate molecules to create products that are more soluble and more readily 
excreted by drug transporters (Guengerich and Shimada, 1991). CYP activities 
may constitute a defense against foreign chemicals, but some have also been 
shown to generate harmful metabolites, such as those of benzo(a)pyrene and 
aflatoxin B1 (Guengerich, 2000). 
2.3.1. CYP3A enzymes 
The term “CYP3A” denotes family 3, subfamily A of the CYP superfamily. 
TheCYP3A enzymes function in the endoplasmic reticulum and require an 
electron transport chain provided by NADPH-Cytochrome P450 reductase 
(Omura, 1999). Among human CYP subfamilies, CYP3A is the most 
prominent- its members are the most highly expressed in the liver and intestines 
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and they catalyze the metabolism of a tremendous variety of substrates, 
including more than half of currently marketed drugs. (Thummel and 
Wilkinson, 1998). The four human CYP3A isozymes, which are numbered 4, 5, 
7, and 43, have extensively overlapping substrate specificities. 
A gene cluster on human chromosome 7q21-q22.1 encodes the CYP3A 
enzymes; interspersed between the active genes are CYP3A pseudogenes, 
dormant remnants of duplication events (Gellner et al., 2001) (Figure 2). At 
least 6 mouse homologs reside in a syngeneic locus on mouse chromosome 5 
(Zaphiropoulos, 2003). All active human CYP3A genes have 13 exons. The 
evolutionary emergence of the CYP3A subfamily predates that of vertebrates, as 
CYP3-like genes are found even among the prevertebrate tunicates (Verslycke 
et al., 2006). CYP3A isoforms are expressed throughout the vertebrate 
subphylum and phylogenetic analyses predict that the common ancestor of all 
vertebrates bore a single CYP3A gene that evolved to generate modern 
CYP3Agene clusters in each species through species-specific gene-duplication 
and recombination events (Mcarthur et al., 2003). 
 
Fig. 2 Human cyp3A locus (Source: NCBI) 
2.3.2. Distribution of CYP3A expression 
Human CYP3A enzymes differ in their temporal and anatomic distributions. 
CYP3A7 expression is seen in vitro but subsides by late infancy in most 
individuals (Stevens et al., 2003). The CYP3A43 enzyme is limited in the 
distribution and magnitude of its expression and it has low catalytic activity for 
CYP3A substrates (Westlind-Johnsson et al., 2003). Adult hepatic and 
intestinal CYP3A activity thus mainly reflects the contributions of CYP3A4 and 
CYP3A5. Furthermore, the frequency of CYP3A5 deficiency varies from one 
population to the other (Kuehl et al., 2001).  
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Among people who express CYP3A5, hepatic levels of CYP3A5 may be only 
25% that of CYP3A4. But the hepatic aggregate CYP3A activity of CYP3A5 
expressers may be exceed that of CYP3A5 non-expressers (Lin YS., et al 2002). 
CYP3A4 and CYP3A5 may be co-expressed in extra-gastrointestinal sites such 
as the placenta (Hakkola et al., 1996). But CYP3A5 is also found in sites where 
CYP3A4 appears to be absent or undetectable. CYP3A5 is the predominant and 
perhaps exclusive 3A isoform in the kidney, including proximal, distal tubules, 
collecting ducts, and renal zona glomerulosa, bronchial, alveolar respiratory 
epithelia and anterior pituitary gland         (Raunio et al., 2005). Extra-
gastrointestinal CYP3A expression is unlikely to contribute significantly to 
overall drug metabolism but may modulate peripheral toxicities and physiologic 
effects of exogenous and endogenous molecules (Raunio et al., 1999). It is 
possible then that variance in some systemic and local adult CYP3A phenotypes 
reflects CYP3A5 polymorphism. There has also been a suggestion that CYP3A5 
and not CYP3A4 genotype modifies risk of a particular chronic nephritis 
(Balkan endemic nephropathy) whose likely etiologic agents include pro-toxic 
chemicals (e.g., ochratoxin A) that are activated by CYP3A enzymes 
(Atanasova et al., 2005). 
2.4. CYP3A5 Genetic Variance 
Early studies of primarily Caucasian subjects suggested that the population-level 
impact of CYP3A5 expression would be small because the vast majority of 
subjects were clear non-expressers (Wrighton et al., 1990). However, 
expression frequency is much higher in non-white populations and generally 
exceeds half among black groups. In every human population studied so far, 
CYP3A5 expression variation mainly reflects the effect of a SNP, A6986G, in 
the third CYP3A5 intron that distinguishes the full expresser allele (called *1) 
from a reduced-expresser allele (*3) (Lamba et al., 2002). The A-to-G transition 
at this position functions as an alternative splice acceptor site that is preferred 
over the canonical exon 4 acceptor site; the frame-shifted variant mRNA 
predicts a truncated protein but the mRNA itself in unstable due to nonsense 
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mediated decay (Busi and Cresteil, 2005). Two additional CYP3A5 SNPs, 
G14690A and 27131- 32insT, respectively define the *6 and *7 alleles and are 
specific to black groups; the frequency of each allele is roughly 0.1. The *6 
allele may cause splicing defects that result in skipping of exon 7; the single-
base insertion in exon 11 that defines*7 results in frame-shifted mRNA, a 
premature stop codon, and truncated protein (Hustert et al., 2001). 
2.4.1. Ethnic differences in CYP3A5 allele frequencies 
The allelic frequency of CYP3A5*3- which is inversely proportional to the 
prevalence of CYP3A5 expression in a population- is roughly 0.27-0.30 among 
African-Americans (Hustert et al., 2001), 0.60 among Southeast Asians 
(Balram et al., 2003), 0.73-0.76 among Chinese and Japanese (Shih and 
Huang, 2002; Hiratsuka et al., 2002), and 0.88-0.96 among Caucasians (King 
et al., 2003). 
2.4.2. The Physiologic Impacts of CYP3A Enzymes 
CYP3A enzymes exhibit broad specificity for steroids. The CYP3As have 
important roles in hydroxylation of testosterone (e.g., at the 2β, 6β, or 15β 
positions) and estrogen (positions 4 and 16α) (Keshava. et al., 2004). It can be 
induced by various compounds including drugs, pesticides, and carcinogens, 
resulting in high CYP3A4 levels in liver and other tissues, including mammary. 
Oxidations of these steroids have incompletely defined effects on their 
bioactivities, but may be responsible for some of the associations between 
CYP3A activity and cancers of the prostate and breast. The particular\ reaction 
most pertinent to this review is 6β-hydroxylation (Figure 3). 
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Fig. 3   CYP3A enzymes catalyze steroid 6β-hydroxylation) (Givens et al., 2003) 
CYP3A-mediated 6 β-hydroxylation is a metabolic pathway in vertebrates for 
steroids that include, in addition to androgens, the glucocorticoids cortisol and 
corticosterone, and the mineralocorticoid aldosterone. 6β-hydroxyglucocorticoid 
products of CYP3A catalyzed reactions stimulate sodium transport across A6 
toad kidney cells and induce sodium retention and increased Creatinine 
clearance in rats (Matsuzaki et al., 1995). 
CYP3A enzymes may modulate of A6 sodium transport through a 
mineralocorticoid receptor (MR)-mediated mechanism (Morris et al., 1998). 
Immunohistochemistry detects CYP3A proteins in rat kidney, human distal 
tubules and collecting ducts (Murray et al., 1999), the principle sites at which 
corticosteroids stimulate sodium reabsorption. 6 β-hydroxysteroids have been 
postulated to exert mineralocorticoid-like renal effects (Clore et al., 1992). The 
findings of these studies present some confusion; however, as 6β- 
hydroxycortisol appears not to activate the MR but may antagonize it and 
appears not to act through the glucocorticoid receptor (GR).CYP3A activity, 
along with that of 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2), has 
been proposed to regulate glucocorticoid occupancy of MRs (Morris et al., 
1998). 
Human and animal data suggest the potential clinical importance of excess 
CYP3A activity. Renal CYP3A content and catalytic activity in the 
spontaneously hypertensive rat (SHR) are higher than in the normotensive 
Wistar-Kyoto rat Treatment of SHR with the CYP3A-selective inhibitor 
troleandomycin lowers BP (Watlington et al., 1992). Several human diseases 
associated with elevated blood pressure, including Cushing’s syndrome and pre-
eclampsia (Clore et al., 1992), are characterized by increased urinary excretion 
of 6β-hydroxycortisol, a marker of in vivo CYP3A activity. A single study 
showed increased serum 6β-hydroxycortisol levels among essential hypertensive 
relative to normotensive individuals (Kornel et al., 1975). Another 
demonstrated that a high-sodium diet caused an increase in urinary 6β-
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hydroxycortisol among sodium sensitive African-American subjects in contrast 
to a decrease among those who were sodium-resistant (Sica et al., 1996). But it 
is not known whether elevated 6β-hydroxycortisol levels in these conditions 
truly reflect an increase in CYP3A activity or merely a spill over of increased 
cortisol levels into the CYP3A pathway, or whether 6β- hydroxysteroids play 
significant pathophysiologic roles in these diseases. 
The involvement of CYP3A enzymes in vitamin D metabolism reasonably 
suggests an ability of CYP3A5 to modify the physiologic effects of sunlight 
exposure. During childhood, vitamin D deficiency can cause a number of 
rachitic skeletal features, including a shallow pelvis, which could negatively 
affect reproductive fitness (Wells, 1975).High CYP3A activity might have 
become detrimental at progressively polar latitudes; decreasing CYP3A5 activity 
would then parallel the loss of melanin that may enable ultraviolet light to form 
cholecalciferol in people living toward the poles (Neer, 1975; Jablonski and 
Chaplin, 2000). CYP3A-mediated decreases in vitamin D may have had a 
secondary effect upon blood pressure and renal sodium balance- vitamin D is a 
negative regulator of the renin-angiotensin-aldosterone system  (Li YC et al.,  
2004) and vitamin D levels are inversely associated with blood pressure and the 
risk of hypertension (Scragg et al., 2007 ). Vitamin D levels may be decreased 
in pre-eclamptic women (Halhali et al., 2007). Lastly, vitamin D controls 
activity of the insulin-like growth factor (IGF) system, an important determinant 
of birth weight (Capoluongo et al., 2007). Thus, CYP3A activity may play 
important roles in the modulation of reproductive fitness by vitamin D. 
Ideas about vitamin D and sunlight exposure parallel those concerning the 
impacts of heat and sodium demand on African emigrants and their descendants. 
The oldest known fossilized skeletons of modern humans to be found outside of 
the African continent- on the Arabian peninsula- date back to 100,000 years ago 
(Stringer and Andrews, 1988). Into the warm and humid African climate of 
that era arose a relatively hairless group with a tremendous capacity to sweat that 
aided in evaporative cooling but also imposed a risk for large losses of water and 
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of sodium, the most critical ionic regulator of mammalian osmosis and 
extracellular volume. Low sodium content of tropical soil may have added to the 
risk of volume depletion and dehydration (Gleiberman, 2007). It is likely that, 
among these early humans, those who had an enhanced ability to retain sodium 
and water enjoyed a significant survival advantage. Retention of these abilities at 
less stressful altitudes might have harmed reproductive success, as demonstrated 
by the ability of antidiuretic hormone (vasopressin), normally produced in 
response to dehydration, to cause preterm pregnant uterine contractions 
(Akerlund, 2002). A role for CYP3A5 in the response to the threat of 
dehydration may be supported by the finding that human CYP3A expression, 
like that of aquaporin-2(aqp2), increases in response to ambient hypertonicity. 
2.5. RAAS pathway 
Central to the physiological control of sodium and water balance is the renin 
angiotensin- aldosterone system (RAAS).Classically, the renal juxta-glomerular 
apparatus (JGA) responds to a decrease in blood pressure or in the rate of 
sodium delivery to the kidney by releasing renin, which cleaves hepatically 
secreted AGT to produce the angiotensin I (AT-I). The angiotensin-converting 
enzyme (ACE), which is found primarily in pulmonary vascular beds, processes 
AT-I into angiotensin II (AT-II). AT-II has a number of functions that include 
vasoconstriction and increasing aldosterone synthesis and secretion by adrenal 
zona glomerulosa cells. Aldosterone secretion leads to increased renal sodium 
and water reabsorption (Nakajima et al., 2004). Resetting of sodium and 
volume homeostasis causes feedback inhibition of renin release, decreasing AT-
II production. The RAAS system was likely critical for early human survival. 
But when salt availability is not limited, excess RAAS activity may be 
detrimental; it has been implicated, for instance, in pre-eclampsia (Ward et al., 
1993). Balance between sodium avidity’s positive and negative effects might 
thus have shifted with heat stress and sodium demand. Direct interactions 
between CYP3A activity and the RAAS pathway have not been shown, but the 
CYP3A metabolic partner P-gp/MDR1 has been implicated in RAAS 
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modulation. P-gp transports many CYP3A substrates- including aldosterone and 
cortisol (Ueda et al., 1992; Parker et al., 2006) is expressed in the distal renal 
tubules and the adrenal cortex, and is an important component of the blood brain 
barrier in humans and in animal models (Muller et al., 2003). Subjects 
homozygous for an MDR1 reduced-expresser allele (3435T) gene show an 
exaggerated increase of serum aldosterone in response to angiotensin II infusion 
and fail to appropriately increase urinary sodium excretion in response to salt 
loading (Zolk et al., 2007).There is reason to suspect that the prehistoric 
CYP3A5 expression modulated physiologic control of sodium balance (Kuehl et 
al., 2001). But the truth of this contention is likely unknowable. With respect to 
its modern importance, the most obvious hypothetical harm of high CYP3A5 
expression is a risk of high blood pressure sodium avidity in the setting of a 
modern abundance of dietary salt might lead to hypervolemia and/or 
hypertension .Hypertension itself is a major continuous risk factor for disability 
and death related to disease of the coronary vessels and peripheral vasculature, 
cerebrovascular accidents, and renal disease. It is perhaps worth noting that not 
only are people of African descent the most frequent CYP3A5 expressers but 
also that African-Americans have the highest global rates of sodium sensitivity 
and HTN (Weinberger, 1996). Both hypertensive and normotensive blacks 
demonstrate, on average, lower plasma renin levels than whites (Sagnella, 
2001). This consistent finding may indicate a decreased capacity for renal 
sodium excretion among African-Americans or an increased tendency toward 
sodium reabsorption by unidentified mechanisms. Potentially related to 
increased rates of hypertension among African- Americans is a higher frequency 
of pregnancies that result in low-birth weight babies. A number of epidemiologic 
studies demonstrate an association between low birth weight or prematurity and 
the risk of adult hypertension. Some of the effects of 6β-hydroxycorticosterone 
may mimic classic mineralocorticoid activity, but it appears to activate sodium 
flux primarily through a distinct non- MR/non-GRA6 cell binding site (Duncan 
et al., 1998). Subsequent studies suggest that such a binding site may be 11β-
HSD2 (Naray and Fejes, 1997), an NADH-dependent enzyme that limits 
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activation of MR by cortisol and corticosterone in aldosterone-sensitive epithelia 
by catalyzing their conversion to their respective 11-oxidized metabolites 
cortisone and 11-dehydrocorticosterone, which are weaker agonists for MR (Fig. 
4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 11β-HSD2 limits glucocorticoid transactivation of mineralocorticoid receptors 
(Givens et al., 2003) 
Genetic 11β-HSD2 deficiency causes the syndrome of apparent 
mineralocorticoid excess (AME), so named because its features of hypertension 
and hypokalemia would suggest high aldosterone levels. Fig. 5 shows the effect 
of CYP3A activity on renal sodium transport.  
Aldosterone 
MR 
Cortisol                              Cortisone 
11β-HSD2 
ENaC 
subunits 
SGK1 
 
20 
 
The particular promise of the CYP3A system lies not only in their possible 
etiologic role in HTN but also in their capacity to metabolize medications that 
include antihypertensives such as the calcium-channel blockers; thus, CYP3A 
activity may not only influence the susceptibility to HTN but also the response 
to some pharmacologic therapies. Because of this potential CYP3A “double 
effect”, this system may be a promising target for novel drug therapy. 
 
 
 
 
                                                     
  
 
 
 
 
 
 
 
Fig. 5   Proposed mechanism of 6β-hydroxysteroid effect on renal sodium transport. 
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3.1. Study population 
The study was performed in the post-graduate department of Internal Medicine, 
of Government Medical College Srinagar and department of Biochemistry 
university of Kashmir Srinagar. Only admitted patients were included in the 
study. Patients who had hypertension (as defined by JNC-7 report) were 
included in the study and were called as cases. Admitted patients who were non-
hypertensive, but had some other disease were taken as controls. 
After getting ethical committee clearance, the study was proceeded as per 
following protocol.     
3.1.1. Cases 
No restrictions were made amongst the patients with essential hypertension, 
gender or age. 
Inclusion criteria 
Subjects only natives of Kashmir. 
Essential hypertension as defined by JNC-7 report.  
Exclusion Criteria 
Patients below the age of 15 years were not included. 
Patients suffering from secondary hypertension were not taken. 
3.1.1.2 Controls 
Controls were equal matched to the cases by gender and age. 
Inclusion criteria 
Non-hypertensive subjects without clinical laboratory evidences of 
cardiovascular, and other systemic disorders likely to influence the blood 
pressure homeostasis of the body  
Subjects should be from Kashmir population 
Medical History review: was prepared while going through the record. The 
important points which were noted include the duration of hypertension, the 
presence of any hypertensive complications, other co-morbid illness. The review 
also included the detailed history regarding intake of medicine which themselves 
produce hypertension as their side effect.  
3.2. Blood samples 
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The blood samples were taken by an experienced nurse under all aseptic 
precaution. The samples were mostly taken from right cubital vein. In some 
patients who had difficulty in getting cubital venous sample, the samples were 
taken from veins of the dorsum of the right hand. The vein was punctured using 
disposable syringe (Dispo vein- Korea 5ml syringe, 22 G beveller needle). The 
punctured site was covered with medicated adhesive tape and the site was 
pressed to 30 sec to 1min to prevent the subcutaneous extra-vasation of blood.  
 Two ml (2 ml) peripheral venous blood of was collected in an EDTA coated 
sterilized plastic vials and stored at -20°C for further use along with the proper 
consent of patients. The samples were bar-coded, each bar-code number was 
written on case/ control information from which contains the basic information 
like name, age, sex, other environmental and clinical features like history of 
smoking, alcohol intake. 
Chemicals/Enzymes Source 
Proteinase K Sigma 
Chloroform Qualigens 
Isoamyl alcohol Qualigens 
EDTA-disodium CDH 
SDS Sigma 
Tris-HCl Himedia 
Magnesium chloride Sisco Research Lab 
Ethanol JiangsuHuaxi International Trade Co.Ltd 
Phenol Qualigens 
Sodium acetate S.D. Fine Chem.Pvt Ltd 
Ethidium bromide Himedia 
Bromophenol blue Himedia 
Tris – base Himedia 
Acetic acid Qualigens 
Sucrose Sisco Research Lab 
Sodium hydroxide RANKIN 
Sodium chloride Sisco Research Lab.Pvt.Ltd 
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Agarose low EEO Sisco Research Lab.Pvt.Ltd 
Isopropanol Qualigens 
Ammonium Chloride D.D. Fine Chem.Pvt.Ltd 
Taq DNA polymerase GENETAQ
TM
 
dNTPs Sigma 
100bp Ladder Sigma 
Oligonucleotides Sigma  
Ssp1 Fermentas 
 
3.4 Reagents 
3.4.1. Reagents for DNA Extraction 
Chloroform Isoamyl alcohol (CIA) 
Chloroform      24.0ml 
Isoamyl alcohol     1.0ml 
Chloroform: isoamyl alcohol, in the ratio 24:1 was prepared by mixing 24 ml of 
Chloroform and 1 ml of isoamyl alcohol. The solution was stored at 4˚C in dark 
bottle. 
DNA storage buffer: 
0.5 M EDTA      0.01 ml 
1 M Tris      0.5 ml 
Final volume was made 50 ml with sterile distilled water. 
Lysis buffer 
1 M Tris      2.0ml 
0.5M EDTA      400µl 
10% SDS      30.0ml 
Final volume of the solution was made 100ml with sterile distilled water. 
Lysis solution 
1 M Ammonium chloride    15.5ml 
1M Potassium bicarbonate    1.0ml 
0.5 M EDTA      200µl 
Final volume was made 100ml with sterile distilled water. 
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Proteinase K 
Proteinase K      10mg 
Proteinase k was dissolved in 1 ml of demonized water and stored at -20˚C in 
aliquots of 1 ml each. 
 
SE Solution 
5 M Sodium chloride    3ml 
0.5 M EDTA      8ml 
Final volume was made 200ml with sterile distilled water. pH was adjusted to 8. 
SDS (10%) 
SDS       10g 
SDS was dissolved in 100 ml sterile distilled water. 
Sodium acetate (3M) 
Sodium acetate      40.83g 
Sodium acetate was dissolved in 100ml sterile distilled water; pH of the solution 
was adjusted to 5.0 using acetic acid. 
Saturated Phenol 
0.2% β- mercaptoethanol 
8-hydroxy quinoline 
0.1 M Tris chloride buffer    800ml 
0.5 M Tris chloride buffer    1000ml 
Phenol      1000ml 
The mixture obtained by adding equal volume of 0.5M Tris-Cl buffer and melted 
phenol was stirred for 15 min on magnetic stirrer. Two phases were allowed to 
separate. Upper aqueous phase was removed and equal volume of 0.1 M Tris-
chloride buffer was added. The saturation with 0.1 M Tris-Cl buffer was 
repeated till phenol >7.8 pH was obtained. A pinch of β-mercaptoethanol and 8-
hydroxy quinoline was added. Phenol was stored at 4˚C in a dark bottle. 
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3.4.2. Reagents for Agarose Gel Electrophoresis 
Agarose (1%)        
Agarose      1.0 g 
Buffer       100ml 
EtBr       5.0µl 
Agarose was dissolved in a buffer and heated till a clear solution is formed. EtBr 
was then added to the solution. 
Bromophenol Blue 
Bromophenol Blue     0.4g 
Sucrose      20.0 g 
Bromophenol blue was dissolved in 100ml of distilled water. 
From the above stock solution 31.25ml was taken and sucrose was added. Final 
volume was made 50ml with distilled water. 
Ethidium Bromide 
Ethidium bromide     10mg 
Ethidium Bromide was dissolved in 1ml of distilled water. The solution was 
stored in a dark bottle at 4˚C. 
50x TAE (pH 8.0) 
Tris base      242g 
0.5M       100ml 
Glacial acetic acid     57.1ml 
Final volume was made 1000ml with distilled water. 
1x TAE (pH 8.0) 
50 x TAE      20ml 
Final volume was made 1000ml with distilled water. 
3.4.3. Reagents for PCR: 
Stock 
Deoxyribose nucleotide triphosphate (dNTP) 10mM each dATP, dGTP, dCTP 
and dTTP 
Taq polymerase (5U/ml) 
10x Taq buffer Primers: 100mM in sterile demonized water (Sigma)  
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100bp DNA ladder (100µg/ml) 
3.5. Genetic Analysis 
For the analysis of polymorphisms, DNA was extracted from whole blood and 
was followed by PCR amplification of desired fragment. These amplified 
products were further analyzed by nucleotide sequencing. 
3.5.1. DNA Extraction by Phenol-chloroform method 
Blood samples (2ml) were obtained from the patients in the EDTA coated plastic 
vials and genomic DNA was isolated by Phenol-Chloroform method (Sambrook 
and Rusell, 3
rd
 edition 2001).  
1. First cells were lysed with 4ml of freshly prepared Lysis buffer (15.5mM 
NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA) with gentle mixing and kept at 
-20
o
C for 15 minutes. 
2. The tubes were then centrifuged at 8000 rpm for 10 min and then 
supernatant was discarded. 
3. The pellet was resuspended in 2 ml of SE, 100µg/ml Proteinase K and 100 
ml of 10% SDS. The solution was incubated at 37
o
C overnight. 
4. On the next day, equal volumes of Tris-saturated-phenol (pH 8) was added 
to the sample in the tube and mixed thoroughly by inverting the tube for 15-
20 min. 
5. The tubes were then centrifuged at 6000 rpm for 10 minutes. The aqueous 
supernatant was transferred to fresh tubes and to it was added an equal 
volume of phenol-CIA (chloroform-isoamyl alcohol). 
6. The tubes were shaken gently for 15 minutes and then centrifuged at 7000 
rpm for 10 minutes. 
7.  The supernatant formed was transferred to fresh tube and to it is added an 
equal volume of CIA.  
8. The tubes were again shaken gently for 15-20 minutes and then centrifuged 
at 8000 rpm for 10 minutes. 
9. To the supernatant was added an equal volume of chilled ethanol and 0.1 
volume of sodium acetate, the DNA precipitated immediately. 
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10. After retrieving the DNA, it was washed thrice with 70% ethanol. DNA was 
then dissolved in 5 ml of DNA storage buffer and stored at 4
o
C for future 
use. 
3.5.2. Qualitative and Quantitative Analysis Genomic DNA 
Qualitative Analysis 
The quality of the genomic DNA was examined by gel electrophoresis using 1.0 
% agarose gel. Initially, 1g of agarose and 100ml of 1x TAE buffer were taken 
in conical flask and heated on the heating mantle for 5-10 min. After that 2µl of 
ethidium bromide (10mg/ml) were added and gel solution was poured into the 
tray and allowed to set for 20 minutes. The gel was submerged in 1x TAE 
buffer. 2µl of each DNA sample was mixed with 1µl of 1x DNA loading dye (1x 
loading dye consists of 4.16 mg bromophenol blue,4.16 mg xylene cyanol and 
0.66g sucrose in1ml water) and was loaded in the gel. Electric current was 
applied at 20 volt until DNA enters in to the gel and was raised to 50 volt for rest 
of the run. Run was stopped when the dye had travelled nearly two third of the 
gel. Gel was visualized by a Gel doc system (AlphaimagerTM 2200, Alpha 
Innotech Corporation) under UV light and picture was captured by using CCD 
camera system (Fig. 6). 
Quantitative Analysis 
The quantity of the DNA was estimated by making appropriate dilutions to 
determine the optical density at 260 nm and 280 nm by double beam 
spectrophotometer (Spectron 2206) and the concentration was determined using 
equation 
                                   DNA (µg/ml) = A260 x 50 x dilution factor 
 The ratio of A260/A280 nm was calculated and the DNA sample for which the 
ratio was 1.6-1.9 was considered for the future use. The DNA was stored at 4
o
C 
for a short time but the vials were kept at -20
o
C for longer duration storage. 
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Fig. 6  Representative gel picture of the genomic DNA isolated from the 
human blood samples analyzed by 1% agarose gel electrophoresis 
 
3.5.3 Genotyping of CYP 3A5 *3 Gene and Restriction Enzyme Analysis 
After Agarose gel electrophoresis it was found that concentration and purity of 
genomic DNA is desirable, the desired fragment of DNA i.e., CYP 3A5*3 gene, 
was amplified by polymerase chain reaction (PCR). After standardizing all the 
parameters of PCR like varying annealing temperature, dNTP, primer and 
template concentration, the CYP 3A5*3 gene was amplified. PCR was 
performed in total volume of 25 µl for restriction digestion and 50 µl for direct 
sequencing. The PCR reactions were composed of 100 ng of genomic DNA, 
0.2mM dNTPs, 0.4 pmoles/µl of each primer and 0.2 U/µl of Taq polymerase in 
1x PCR buffer (Table 2).  PCR tubes containing reaction mixture ware mixed 
and placed in a 96 well automated thermal cycler (Applied) for amplification. 
After placing the tubes within thermal cycler, different temperatures were set as 
given in the table 3. The primer pair used for amplification of CYP 3A5*3 genes 
was: 
Forward primer:   5
/
-CATGACTTAGTAGACAGATGAC-3
/
 
Reverse primer:     5
/
- GGTCCAAACAGGGAAGAAATA-3
/
 
Lyophilized primer stocks were diluted first to 100pg/µl concentration and then 
working was made 20pg/µl using miliQ water. Amplification and specificity of 
Genomic  
DNA 
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amplicon obtained in the PCR reaction was analyzed by 2% agarose gel 
electrophoresis. The gel was visualized on UV-illuminator and photographed on 
the Gel Doc System. The concentration of amplified PCR products was 
approximated by comparison with the intensity of corresponding bands in 100 
bp DNA ladder. The  final PCR product of 293 bp was obtained and was 
digested by restriction enzyme SspI (Fermntas ) for 4 h at 37 
o
C. Digested 
products were separated on a 3% agarose gel. Samples with CYP3A*1/*1 
genotype gave 148-, 125-, and 20-bp bands, whereas samples with 
CYP3A5*3/*3 genotype 168- and 125-bp bands. Sequencing was commercially 
done using the services of SciGenomics Kerala. For purification and sequencing, 
50 μl of unpurified PCR product samples were sent along with 50μl of 20μM 
Forward & Reverse primers. 
 
         Table 2 Volume of different reagents used for 25 µl reaction 
Reagent Volume used 
10X PCR reaction buffer 2.5 µl 
MgCl2 2. 2 µl 
dNTP mix 0.6 µl 
Forward Primer  0.3 µl 
Reverse Primer 0.3  µl 
Genomic DNA 3.0  µl 
Taq DNA polymerase  0.3  µl 
MilliQ water                       15.8 µl 
Total Volume 25 µl 
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   Table 3 PCR cycling parameters 
 
 
Statistical Analysis  
The χ2-test was used to examine the differences in the distribution of genotypes 
between cases and controls. OR with 95% CI were computed using 
unconditional logistic regression (GraphPad Prism 5) and adjusted for age and 
gender. 
 
 
 
 
 
 
 
 
 
 
Steps Temperature 
o
C Time 
Initial Denaturation 
 
Denaturation 
 
Annealing  
 
Extension 
 
Final extension 
95 
 
95 
 
56.5  
 
72 
 
72 
7 minutes 
 
50 seconds 
 
1 minute         35 Cycles     
 
1 minute 
 
10 minutes 
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Essential hypertension (EH) is a polygenic and multifactorial disorder that 
results from genetic and/or environmental factors. This disease has no 
identifiable origin, but results from a disturbance of various parameters 
regulating blood pressure (BP) such as several circulating and local 
neurohumoral and vasoactive factors. Genetic polymorphisms were associated 
with an increase in the risk of developing this disease and these are integral to 
the development of genetic marker in identifying the individuals at risk. In this 
hospital based case control study we investigate the association of the 
CYP3A5*3 rs776746 (6986 𝐴 → 𝐺) allele in hypertensive cases and healthy 
controls of Kashmiri valley.  
We included one hundred fifty confirmed hypertensive cases and an equal 
number of age and gender matched controls in this study. On analyzing the data 
it came out that, out of 150 cases registered, 78 were males with mean age 
(60.55±11.19) and 72 were females with mean age (60.11±9.92) years.  Out of 
these cases, 27(18.0%) were found in the age group of 40-50 years, 48 (32%) of 
cases were found in the age group of 50-60 years, 50 (33.33%) were in the age 
group of 60-70 years and 21(14%) were in the age group of above 70 years. 
Carriers of CYP3A5 were slightly younger than non carriers. (Table 9). 
Of all the regions of the Kashmir division, highest number of cases turned out 
from the urban area (64%) and least number of cases were from rural areas 
(36%), while as in case of controls (45.33%) were from urban areas and 
(54.66%) were from rural areas. Also the use of tobacco in the form of cigarette 
smoking and Hukka was seen in about 45% of cases and 14.66% of controls 
(Table 4).  
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 Table 4.  Demographic characteristics of essential hypertension cases and 
controls 
Demographic Features          HTN Cases (n=150) Controls (n=150) 
Age (Years mean ± S.D) 60.55±11.19 60.11±9.92 
Gender 
                  Male 
                  Female 
 
78 (52%) 
72 (48%) 
 
79 (52.6%) 
71 (47.3%) 
Systolic pressure (mmHg) 139.7 ± 17.47 
(90.00 - 200.0) 
120.3 ± 7.98 
(100.0 - 130.0) 
Diastolic pressure (mmHg) 89.51 ± 10.71 
(60.00-120.0) 
80.93 ± 6.27 
(60.00-100.0) 
Smoking 45(45%) 22(14.66%) 
Rural  54(36%) 82(54.66%) 
Urban  96(64%) 68(45.33%) 
n= no. of individuals 
Value represents ± SD 
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4.1. Clinical features of essential hypertension patients of Study population 
The patients with HTN were diagnosed in the Department of Internal Medicine, 
Government Medical College Srinagar kashmir. The diagnosis of essential 
hypertension was based on the standard clinico-hematological parameters and by 
measuring blood pressure. Clinical and Biochemical characteristics of HTN 
subjects who were genotyped for CYP3A5*3 gene are shown in Table 5.  
 
Table 5. Clinical characteristics of Study Subjects 
Characteristics 
All subjects 
(n=150) 
Males 
(n=79) 
Females 
(n=71) 
Age (Years) 60.55 ± 11.19 61.13 ± 11.02 59.10 ± 11.43 
Systolic pressure 
(mmHg) 
139.7 ± 17.47 
(90.00 - 200.0) 
138.2 ± 18.30 
(90.00 - 200.0) 
141.3 ± 16.47 
(90.00-190.0) 
Diastolic 
pressure (mmHg) 
89.51 ± 10.71 
(60.00-120.0) 
89.82 ± 11.94 
(60.00-120.0) 
89.15 ± 9.219 
(60.00-120.0) 
Haemoglobin 
(g/dl) 
11.94 + 1.61 11.89 + 1.14 10.75  ±  1.15 
Serum sodium 
(mEq/L) 
138.7 ± 16.50 137.1 ± 22.02 140.4 ± 5.783 
Serum potassium 
(mEq/L) 
4.080 ± 0.7730 4.109 ± 0.8212 4.048 ± 0.7200 
Serum urea 
(mg/dl) 
35.11 ± 8.113 34.35 ± 7.830 35.95 ± 8.391 
Blood Glucose 
(mg/dl) 
119.3 ± 46.93 118.6 ± 40.74 120.1 ± 53.27 
Serum 
Creatinine 
(mg/dl) 
1.837 ± 1.909 1.803 ± 1.879 1.876 ± 1.956 
n= no. of individuals 
Value represents ± SD 
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4.2 Analysis of Cyp3A 5*3 Polymorphism 
Polymorphism in the intron 3
rd 
region of the CYP3A5 gene was assessed in this 
study. A single primer set was used to amplify the CYP3A5*3 region which 
produced 293 bp size amplicon.  One hundred fifty genomic DNA samples from 
cases and equal number of healthy controls were taken as templates. The 
reaction conditions and PCR program which was used for amplification is 
described in methodology section. The results showed that all the genomic DNA 
samples were amplified successfully, producing specific amplicon of expected 
size. After amplification 5µl of PCR products were visualized under UV 
exposure after the gel was stained with ethidium bromide as shown in Fig. 7. 
The results of the Polymerase chain reaction-restriction fragment length 
polymorphism analysis (PCR-RFLP) of CYP3A5*3 A6986G is shown in Fig 8. 
The 293 bp amplicon when digested with Ssp1 restriction enzyme breaks the 
wild genotype to three fragments of 148 bp, 125 bp and 20 bp. However,  A to G 
transition at position 6986 results in loss of  restriction site and result in two 
fragments of 168 bp and 125 bp in case of mutant genotype. The digested 
products were analyzed on 3% agarose gel. 
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Fig.7: Representative photograph of the CYP3A5*3 gene amplified 
by Polymerase chain reaction. Lane no. 1 represents 
negative control, Lane no. 2 represents 100bp ladder, Lane 
no. 3, 4, 5, 6, 7 represents 293 bp fragment of CYP3A5*3 
gene amplified by PCR. 
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Fig.8 PCR-restriction fragment length polymorphism analysis 
(PCR-RFLP) of CYP3A5*3 polymorphism. Ssp1 
digested products analyzed on 3%agarose gel 293 bp 
PCR amplicon when digested with restriction enzyme 
cuts the wild genotype to yield three fragments 148 bp, 
125 bp and 20 bp. However, in mutant it results in two 
fragments 168bp and 125bp. 
m- 50 bp DNA ladder. 
Lane 1- Untreated PCR amplicon of 293 bp. 
Lane 5 -Homozygous wild genotype 
Lane 2, 3 - Heterozygous genotype 
Lane 4, 6 and 7 - Homozygous mutant genotype 
 
 
 
 
 
 
LANE      M        1      2       3        4      5       6       7 
148bp 
 
      168bp 
      125bp 
   293bp 
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4.3 Genotypic and Allelic Frequency of CYP3A5 *3 Gene 
Cases 
In the present study 150 confirmed essential hypertension cases belonging to the 
Kashmir division were analyzed for polymorphism in intron 3rd of the CYP3A5 
gene. In these HTN cases the genotypic frequency for homozygous wild type 
(A/A) was found to be 6% (9/150). The genotypic frequencies observed for 
heterozygous genotype (A/G) and homozygous variant (G/G) were 8% (12/150) 
and 86 % (129/150) respectively as shown in the Table (4). The frequency of 
wild allele in HTN patients was 0.1 (30/300) and mutant allele frequency was 
0.9 (270/300). Therefore the percentage calculated for wild and mutant allele of 
CYP3A5 in HTN patients was 10 and 90 respectively (Table 5). 
Controls 
An equal number of normotensive, age and gender matched controls were 
screened for the intron 3
rd
 polymorphism of the CYP3A5 gene. The genotypic 
frequency observed in controls for homozygous wild (A/A) was 2% (3/150). The 
frequencies analyzed for heterozygous genotype (A/G) and homozygous mutant 
(G/G) were 3.33% (5/150) and 94.66 (142/150) respectively, (Table 6). The 
distribution of the three genotypes for the CYP3A5*3 polymorphism confirmed 
well to the predictions of Hardy–Weinberg law.  The frequency of wild allele in 
150 healthy individuals taken as controls was 0.036 (11/300) and mutant allele 
frequency was 0.96 (289/300). Therefore the percentage for wild and mutant 
allele of CYP3A5 in controls was 3.66 and 96.33 respectively (Table 7). 
We observed that the frequency of CYP3A5*3 mutant allele was higher in 
controls as compared to cases and the difference was statistically significant 
(p<0.002), indicating thereby that CY3A5*3 has some protective role. 
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Table 6. Frequency of CYP3A5 Genotype in essential hypertension patients and 
controls 
Polymorphism 
Cases 
n (%) 
150 
Controls 
n (%) 
150 
OR (95% 
CI) 
P value 
A/A (1*/1*) 9 (6.00) 3 (2.00) 1 - 
A/G(1*/3) 12 (8.00) 5 (3.33) 
1.25 
(0.23-6.57) 
0.800 
G/G(3*/3) 129 (86.00) 142 (94.66) 
3.30 
(0.87-12.47) 
0.063 
 
Table 7. The distribution of CYP3A5 allele in essential hypertension patients and 
controls 
Polymorphism Alleles 
Cases 
n
s
 (%) 
300 
Control 
n
s
 (%) 
300 
OR (95% 
CI) 
P value 
CYP3A5*3 
6986 𝑨 → 𝑮 
A (*1) 30(10.00) 11(3.66) 1 - 
G (*3) 270(90.00) 289(96.33) 
2.91(1.43-
5.94) 
0.002 
n
s
 = Number of Alleles 
statistically significant P<0.05. 
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4.3.1 Association of CYP3A5
*
1 with Blood Pressure and hypertension 
Overall we observed that the presence of the CYP3A5*1 allele exhibited no 
effect on systolic blood pressure (SBP) and diastolic blood pressure (DPB). The 
observed adjusted difference between CYP3A5*1/*1+CYP3A5*3/*1 individuals 
compared with CYP3A5*3/*3 individuals for SBP and DBP was not statistically 
significant (Table 8). The CYP3A5 genotype distribution in different age groups 
and genders is shown in Table (9).  No significant association was observed 
between CYP3A5*3 polymorphism and age or gender of the HTN patients 
which indicates that CYP3A5*3 polymorphism might be independent risk factor 
and is not influenced by age and gender of the patient (Table 9)   
 
Table 8.   Association of genotype with systolic and diastolic blood pressure  
 
CYP3A5 
genotype 
 
*3/*3 
 
*3/*1 
 
*1/*1 
 
P value 
(n) 132 10 8 - 
SBP 
(mmHg) 
140.0 ± 17.60 142.0 ± 21.50 131.3 ± 3.536 0.0700 
DBP 
(mmHg) 
89.21 ± 10.89 91.00 ± 11.97 92.50 ± 4.629 0.5469 
n= no. of individuals 
Value represents ± SD 
# Students `t` test (Unadjusted) comparing CYP3A5*3/*3 individuals with CYP3A5*3/*1 + 
CYP3A5*1/*1 individuals. 
Statistically significant P<0.05. 
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Table 9.  Distribution of CYP3A5*3 Polymorphism in essential hypertension 
patients with Respect to age and gender 
 CYP3A5*1 
 
CYP3A5 1*/3* CYP3 A5*3 Allele 
frequency 
 
Parameters n(%) n(%) n(%) A G 
Age(Yrs) 
<40(4) 
40-50(27) 
50-60(48) 
60-70(50) 
>70(21) 
 
0(0.00) 
1(3.70) 
5(10.42) 
1(2.00) 
1(4.76) 
 
0(0.00) 
1(3.70) 
3(6.25) 
5(10.00) 
1(4.76) 
 
4(100) 
25(92.60) 
40(83.33) 
44(88) 
19(90.48) 
 
0.00 
0.055 
0.135 
0.070 
0.071 
 
1.00 
0.944 
0.865 
0.930 
0.929 
χ2 = 5.57; df=8, p=0.6948 
Sex 
Male(79) 
Female(71) 
 
6(7.59) 
2(2.82) 
 
9(11.40) 
1(1.41) 
 
64(81.01) 
68(95.77) 
 
0.133 
0.035 
 
0.867 
0.965 
χ2 = 8.11; df=2, p= 0.501 
n= Number of Individuals  
Statistically Significant p>0.05  
 
4.3. 2 Sequence Analysis 
Sequencing of fifty samples for the conformation of RFLP analysis and potential 
variation in the nucleotide sequence of the CYP3A5*3 gene was done 
commercially using the services of Sci Genomics Kerala. Alignment of all the 
sequences pertained to DNA samples of few cases and controls was done with 
respect to control sequence. Sequencing results for CYP3A5*3 for potential 
SNPs for cases and controls are respectively shown by chromatograms in Figure 
9 and 10. These chromatograms indicate the presence of single A→ 𝐺 
polymorphism at 6986 position in intron 3rd region of CYP3A5 gene The 
representative chromatograms of wild type A allele and the variant allele with 
A→ 𝐺 change are given in the Figure 11 and 12. Direct sequencing results were 
in agreement with the RFLP pattern, thereby confirming the reliability of the 
results obtained by RFLP method.    
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Fig.9  Representative Chromatogram of direct sequencing for CYP3A5 gene wild allele   
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Fig. 10 Representative Chromatogram of direct sequencing for CYP3A5 gene mutant 
allele   
 
 
 
 
 
 
 
 
Wild 
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Fig. 11 Representive chromatogram of  Direct sequencing for  CYP3A5 
wild individuals . The CYP3A5 of wild individuals contains a 
A nucleotide  base at 6986  position. 
 
      
 
Fig. 12 Representive chromatogram of  Direct sequencing CYP3A5 
mutant individuals. The CYP3A5 of mutant individuals 
contains a A→ 𝐺 substitution at 6986 position. 
 
 
 
 
A6986G 
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CYPs are a superfamily of monooxygenases that are responsible for the 
oxidative metabolism of more than half the drugs currently available. CYP3A5 
is abundantly expressed in the liver and small intestine, but only in the 30% of 
whites and 70% of blacks who possess ≥1 CYP3A5*1 allele. Research into the 
role of the CYP3A5 polymorphism in BP regulation was stimulated by an initial 
study in a small group of African–Americans in which higher BPs were reported 
in individuals carrying the CYP3A5*1 allele (Givens et al., 2003). 
Subsequently, additional studies have analysed the role of CYP3A5 on blood 
pressure in different populations and have produced controversial results 
(Kreutz et al., 2005; Ho et al., 2005; Neville et al., 2012). In this regard, it is 
important to consider that the frequency of CYP3A5∗1 carriers, i.e. high 
expressers’ of CYP3A5, shows extreme variations across human populations and 
is significantly correlated with the distance from the equator, with the highest 
frequency of approx. 70% observed in Africans and the lowest, with approx. 
10%, found in European Caucasians (Thompson et al., 2004). CYP3A 
expression in the kidney is moderate as compared to the liver and is 
predominantly CYP3A5 (Haehner et al., 1996). There are several lines of 
evidence consistent with an association between CYP3A enzyme activity and 
blood pressure or sodium retention. As early as 1975, it was shown that 6α-
hydroxycortisol and 6 –β hydroxycortisol were higher by an average of 48% in 
patients with essential hypertension compared with normotensive subjects 
(Kornel et al 1975). Interestingly it has been observed that salt sensitive 
hypertension is more prevalent in African –American than any other ethnic 
group and so is the frequency of wild type CYP3A5*1 allele (Givens et al., 
2003) found 8 fold higher renal CYP3A5 content and 18 fold higher CYP3A 
activity in kidney microsomes from CYP3A5 *1/*3 compared to CYP3A5 *3/*3 
individual. They also reported significant association between CYP3A5 
polymorphism and blood pressure. The mean systolic blood pressure of wild 
type homozygote was 19.3 mmHg higher than that of mutant homozygote’s 
CYP3A5 *3/*3 (Givens et al., 2003). It was found that CYP3A5*1 was more 
frequent in hypertensive African- American than normotensive. These studies 
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clearly indicated that high CYP3A5*1 allele frequency in African-American 
may contribute to a high prevalence of salt sensitive hypertension in this 
population. As a result of high renal expression of CYP3A5 in normal 
homozygote’s there was more Na+ retention which resulted in high blood 
pressure. Increased frequency of CYP3A5*1 and prevalence of hypertension in 
African American compared to Caucasians is well documented. Since blood 
pressure homeostasis is strongly associated with Na
+ 
regulation and salt 
sensitivity population specific differences in susceptibility to hypertension could 
be explained by variation in CYP3A5 gene. The “sodium retention hypothesis,, 
(Nakajima, et al., 2004) proposes that human population living in hot, humid 
areas with low sodium availability like Africa adapted to their environment by 
retaining salt whereas population in cooler temperature climates adapted to 
conditions of greater sodium availability .This hypothesis provides a general 
framework for interpreting the patterns of variation observed in genes involved 
in sodium haemostasis. An ancestral allele that increase salt and water retention 
such as CYP 3A5*1 confers selective advantage. (Thompson et al., 2004) 
reported a decrease in CYP 3A5*1 frequency and an increase in CYP3A5*3 
frequency with distance from the equator. A promoter A   G variant exists in 
strong linkage disequilibrium with M235T variant in AGT; the combination of 
these two was reported to be associated with hypertension (Wu et al., 2004). 
CYP 3A5*1/*3 polymorphism appears to have similar phenotypic effects as 
these AGT variants. Interestingly, AGT variant exhibited a similar geographic 
distribution and were significantly correlated in frequency with CYP3A5 *1/*3 
(Thompson et al., 2004). Thus a hospital based case-control study was devised 
which was aimed to evaluate the association of the CYP3A5*3 rs776746 (6986 
𝐴 → 𝐺) allele in hypertensive cases and healthy controls of Kashmir valley, this 
study consists of one hundred fifty confirmed essential hypertension cases (78 
males and 72 females; age (mean ± S.D) 60.55 ± 11.19 years) and also equal 
number of age and gender matched normotensive controls (79 males and 71 
females; age (mean ± S.D) 60.11±9.92 years).  We observed a higher 
representation of hypertensive cases in the age group between 40 and 60. The 
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highest number of the hypertension cases turned out from the urban area with 
total number of 96 (64%) cases recruited for the study and 54 (36%) cases were 
from rural areas patients. The wide difference in the incidence rate across 
different regions of the Kashmir valley suggests the role of some environmental 
exposure of the local population (Shahid et al., 2010).The influence of such 
factors on the incidence rate if any needs to be studied by conducting well 
designed scientific studies. 
The main aim of the present study was to assess the CYP3A5*1 genotype among 
hypertensive cases as high frequency is risk factor for developing essential 
hypertension (Givens et al., 2003).  Gene polymorphism (SNPs) was screened 
by RFLP analysis. The CYP3A5 gene has a common polymorphism (6986 
𝐴 → 𝐺 rs776746) in the intron third. The G allele generates an aberrant RNA 
splicing site and results in a premature stop codon, which causes truncation of 
the CYP3A5 protein. In genetic epidemiology studies, CYP3A5*1 refers to the 
A allele (functional allele) and CYP3A5*3 refers to the G allele (nonfunctional 
allele). The higher frequency of the mutant allele CYP3A5*3 in controls is 
suggestive of its protective role (Langee et al., 2004). In the present study, we 
analyzed the relevance of CYP3A5 polymorphism for blood pressure levels. 
Overall analysis revealed that the presence of the CYP3A5*1 allele exhibited no 
effect on systolic blood pressure (SBP) and diastolic blood pressure (DPB). The 
observed adjusted difference between CYP3A5*1/*1+ CYP3A5*3/*1 
individuals compared with CYP3A5*3/*3 individuals for SBP and DBP was not 
statically significant. Our results substantiate few early findings in which no 
significant differences between CYP3A5 gene with blood pressure and essential 
hypertension was seen in African- Americans and Caucasians (Langee et al., 
2004; Neville et al., 2012).  
The reason for contrary results obtained from several studies remains ambiguous 
and might be attributed to differences in ethnic background and the selection of 
population studied, difference in sample size and gene-environment interaction.  
As the CYP3A5 gene has been implicated in BP regulation in some ethnic 
50 
 
groups, so, additional epidemiological, biological and clinical studies in Kashmir 
population are required to further investigate the role of CYP3A5 in the 
pathogenesis of hypertension. However, it is also important to include more 
genes that participate in the RAAS pathway in order to identify genetic markers 
that may predict individual susceptibility to essential hypertension.  
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